ArticleFrontiers in endocrinology2026
Study on the construction of a risk assessment model for type 2 diabetes complications based on GlycA and HDL1-TC.
Article in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: This study evaluated NMR-derived GlycA and lipoprotein subfractions for stratifying type 2 diabetes (T2DM) complication risk. Methods: A retrospective cross-sectional study included 228 adults with T2DM from two hospitals between January and December 2023. Clinical variables, the NMR-derived inflammatory markers GlycA and GlycB, and lipoprotein subfractions were analyzed. A stepwise logistic model was assessed by ROC analysis, Hosmer-Lemeshow test, bootstrap calibration, and decision-curve analysis. Results: Age, diabetes duration, fasting plasma glucose, GlycA, and HDL1-TC were retained. The model showed good fit (χ² = 7.141, P = 0.521), discrimination (AUC = 0.82, 95% CI: 0.756-0.873), calibration (MAE = 0.021), and higher net benefit than HbA1c/hs-CRP. Conclusions: A model integrating GlycA, HDL1-TC, and clinical factors showed good performance for T2DM complication risk stratification, but causal inference and temporal prediction cannot be established because of the cross-sectional design.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.